Researchers Developed New Alzheimer's Biomarker Platform
A new diagnostic tool uses standard laboratory equipment to measure Alzheimer's proteins with high sensitivity.
Updated on Oct. 7, 2026 in Alzheimer’s
Live Poll
Should medical research focus on simplifying diagnostic tools for use in standard local labs?
Scientists have created the SPLASH platform, an ultrasensitive tool designed to quantify Alzheimer's disease biomarkers from plasma. This development potentially removes the need for specialized, centralized laboratory infrastructure by utilizing standard qPCR hardware.
Why it matters
By enabling precise testing on benchtop equipment without cold-chain storage, this platform could significantly increase global access to early Alzheimer's diagnostics. The ability to process dried plasma spots simplifies logistics for clinical screening.
The platform achieves detection limits between 0.0005 and 0.119 pg/mL across five biomarkers including pTau-217 and Aβ1-42. A multiplexed panel was validated using 69 plasma samples to confirm the tool's diagnostic capabilities.
The details
The SPLASH platform functions as a solid phase ligation assay that integrates seamlessly with standard benchtop qPCR hardware. It targets five specific biomarkers, including pTau-217, NfL, and GFAP, providing researchers with a more portable and efficient alternative to legacy testing methods.
Timeline
The findings were published on October 7, 2026.
The Big Picture
This diagnostic platform follows the trajectory set by the development of the Simoa immunoassay platform, representing a critical shift in neurodegenerative disease screening. The advancement marks a departure from centralized laboratory reliance toward decentralized clinical testing.
This development could eventually simplify how patients are screened for early signs of Alzheimer's by allowing doctors to use common lab equipment. By supporting analysis of dried plasma samples, the tool may reduce the need for cold-chain storage and expedite test results.
The takeaway
The move toward decentralized testing platforms suggests a future where diagnostic biomarkers are analyzed as routinely as common blood work. Simplifying these assays is a necessary step toward making population-level neurodegenerative screening a clinical reality.
Further reading
For more information on the latest advancements in the field, explore our Alzheimer’s section.
Source note: This article includes information reported by Nature.
Live Poll
Should medical research focus on simplifying diagnostic tools for use in standard local labs?
